<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121483</url>
  </required_header>
  <id_info>
    <org_study_id>1245.87</org_study_id>
    <secondary_id>2013-002304-14</secondary_id>
    <nct_id>NCT02121483</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the
      safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18
      years with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
    <description>Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
    <description>Maximum measured concentration in plasma (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
    <description>Maximum measured concentration in plasma (tmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
    <description>Terminal half-life in plasma (t1/2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake.
For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'UGE at baseline' and 'FPG at baseline' as continuous covariates. Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake.
For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'FPG at baseline' as continuous covariate.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1).
For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as fixed effect and 'MDG at baseline' as continuous covariate.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empagliflozin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive a high dose of empagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive a medium dose of empagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive a low dose of empagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin medium dose</intervention_name>
    <arm_group_label>empagliflozin medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin high dose</intervention_name>
    <arm_group_label>empagliflozin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin low dose</intervention_name>
    <arm_group_label>empagliflozin low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Children and adolescents with type 2 diabetes mellitus

          -  Insufficient glycaemic control (HbA1c &lt;=10.5%) despite diet and exercise and/or
             metformin and/or stable basal or MDI insulin

          -  Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and
             fasting C-peptide levels &gt;= 0.85 ng/ml

          -  BMI &gt; 50th percentile for age and sex

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt; 240 mg/dl (&gt; 13.3 mmol/l)

          -  History of acute metabolic decompensation such as diabetic ketoacidosis within 3
             months before the screening visit with the exception of acute de-compensation at the
             time of type 2 diabetes diagnosis

          -  Treatment with weight reduction medications within 4 weeks before randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.87.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.97202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.97203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.87.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>July 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2016</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Empagliflozin 5mg</title>
          <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 10mg</title>
          <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 25mg</title>
          <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): The TS included all patients who were allocated trial medication and had received trial medication (empagliflozin).</population>
      <group_list>
        <group group_id="B1">
          <title>Empagliflozin 5mg</title>
          <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 10mg</title>
          <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 25mg</title>
          <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.7" spread="2.0"/>
                    <measurement group_id="B2" value="14.5" spread="1.9"/>
                    <measurement group_id="B3" value="14.2" spread="2.1"/>
                    <measurement group_id="B4" value="14.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf</title>
        <description>Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
        <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
        <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf</title>
          <description>Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
          <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1150" spread="47.6"/>
                    <measurement group_id="O2" value="1430" spread="17.2"/>
                    <measurement group_id="O3" value="5060" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9490</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1075</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7276</ci_lower_limit>
            <ci_upper_limit>1.1704</ci_upper_limit>
            <estimate_desc>Dose proportionality was assessed based on a power model that describes the functional relationship between the dose and AUC0-inf. Based on the estimate for the slope parameter β, a 2-sided 95% confidence interval (CI) for the slope was computed.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-tz</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).</description>
        <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
        <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).</description>
          <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1110" spread="49.9"/>
                    <measurement group_id="O2" value="1400" spread="17.1"/>
                    <measurement group_id="O3" value="4980" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9597</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1088</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7356</ci_lower_limit>
            <ci_upper_limit>1.1838</ci_upper_limit>
            <estimate_desc>Dose proportionality was assessed based on a power model that describes the functional relationship between the dose and AUC0-tz. Based on the estimate for the slope parameter β, a 2-sided 95% CI for the slope was computed.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum measured concentration in plasma (Cmax).</description>
        <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
        <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured concentration in plasma (Cmax).</description>
          <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" spread="44.5"/>
                    <measurement group_id="O2" value="188" spread="50.2"/>
                    <measurement group_id="O3" value="602" spread="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.8554</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1481</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5504</ci_lower_limit>
            <ci_upper_limit>1.1603</ci_upper_limit>
            <estimate_desc>Dose proportionality was assessed based on a power model that describes the functional relationship between the dose and Cmax. Based on the estimate for the slope parameter β, a 2-sided 95% CI for the slope was computed.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Maximum measured concentration in plasma (tmax).</description>
        <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
        <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Maximum measured concentration in plasma (tmax).</description>
          <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.95" upper_limit="7.92"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.97" upper_limit="4.17"/>
                    <measurement group_id="O3" value="1.78" lower_limit="0.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2</title>
        <description>Terminal half-life in plasma (t1/2).</description>
        <time_frame>Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.</time_frame>
        <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Terminal half-life in plasma (t1/2).</description>
          <population>Pharmacokinetic Set (PKS): The PKS included all treated patients who provided at least 1 primary or secondary pharmacokinetic parameter for statistical assessment.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="19.4" lower_limit="5.46" upper_limit="8.90"/>
                    <measurement group_id="O2" value="7.35" spread="29.3" lower_limit="4.51" upper_limit="10.90"/>
                    <measurement group_id="O3" value="7.80" spread="29.6" lower_limit="4.93" upper_limit="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake</title>
        <description>Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake.
For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including ‘treatment’ as a fixed effect and ‘UGE at baseline’ and ‘FPG at baseline’ as continuous covariates. Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Treated Set (TS) including patients with UGE data on both visits</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake</title>
          <description>Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake.
For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including ‘treatment’ as a fixed effect and ‘UGE at baseline’ and ‘FPG at baseline’ as continuous covariates. Means presented are the adjusted means.</description>
          <population>Treated Set (TS) including patients with UGE data on both visits</population>
          <units>g/24h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="10.24"/>
                    <measurement group_id="O2" value="73.0" spread="10.14"/>
                    <measurement group_id="O3" value="87.4" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake</title>
        <description>Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake.
For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including ‘treatment’ as a fixed effect and ‘FPG at baseline’ as continuous covariate.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Treated Set (TS) including patients with FPG data on both visits</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake</title>
          <description>Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake.
For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including ‘treatment’ as a fixed effect and ‘FPG at baseline’ as continuous covariate.
Means presented are the adjusted means.</description>
          <population>Treated Set (TS) including patients with FPG data on both visits</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" spread="6.53"/>
                    <measurement group_id="O2" value="-16.6" spread="6.29"/>
                    <measurement group_id="O3" value="-20.4" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake</title>
        <description>Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1).
For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including ‘treatment’ as fixed effect and ‘MDG at baseline’ as continuous covariate.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>Treated Set (TS) including patients with plasma glucose profile data on both visits</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5mg</title>
            <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10mg</title>
            <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25mg</title>
            <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake</title>
          <description>Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1).
For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including ‘treatment’ as fixed effect and ‘MDG at baseline’ as continuous covariate.
Means presented are the adjusted means.</description>
          <population>Treated Set (TS) including patients with plasma glucose profile data on both visits</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" spread="7.95"/>
                    <measurement group_id="O2" value="-6.5" spread="9.21"/>
                    <measurement group_id="O3" value="-13.2" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events reported within 7 days following trial drug administration were considered on treatment, up to 8 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin 5mg</title>
          <description>Single dose (1 tablet) of 5mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10mg</title>
          <description>Single dose (1 tablet) of 10mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 25mg</title>
          <description>Single dose (1 tablet) of 25mg, empagliflozin, film-coated tablet administered orally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim (BI)</organization>
      <phone>1800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

